Consultants hosting AF trainees from August 2019 within the speciality of medicine.
Dr David Adlam
My research interests include coronary artery diseases, coronary imaging and using large datasets to understand cardiovascular comorbidity.
Professor Peter Bradding
Pathophysiology of asthma and pulmonary fibrosis with focus on the role of ion channels as therapeutic targets, using human cells (fibroblasts, airway smooth muscle, mast cells) and lung tissue. Wide range of laboratory techniques including immunohistochemistry, confocal microscopy, electron microscopy, qRT-PCR, western blotting, flow cytometry, Ca2+ imaging, patch clamp electrophysiology, ex vivo human lung models and functional cell assays.
Professor Chris Brightling
Christopher Brightling is a NIHR Senior Investigator, Respiratory Theme Lead for Leicester NIHR Biomedical Research Centre and director of the European Respiratory Society Research Collaborations and major research consortia AirPROM, MRC/ABPI COPD (COPDMAP) and EMBER. Research interest immunopathogenesis of airway diseases, particularly asthma, chronic cough and COPD. Current projects include understanding the role of biomarkers in the clinical management of airways disease; interactions between the host and the airway ecology in airways disease; development of new therapies in airways disease; understanding the interactions between mast cells and airway smooth muscle cells in the development of the asthmatic phenotype and migration and remodelling of airway smooth muscle in asthma and COPD.
Dr Maumer Durrani
I am research lead for Rheumatology and PI on commercial as well as portfolio studies. Special interest include Rheumatoid arthritis and biologicas.
Professor Martin Dyer
The Ernest and Helen Scott Haematological Research Institute in the University of Leicester develops and assesses new precision medicines for the lymphoid malignancies. We have active programmes of laboratory and clinically based work, the latter including many cutting-edge Phase 1 clinical trials using small molecules and antibody constructs. Current laboratory projects involve detailed translational studies and collaborative working with CRUK, Pharma and academic groups in London, centred around our Phase I portfolio studying drug mode of action and identifying possible synergistic interactions.
Professor Dean A. Fennell
The Leicester Mesothelioma Programme is focused on developing and testing novel personalised treatments for mesothelioma, a cancer caused by asbestos that is increasing in incidence worldwide. Our genomics studies aim to identify new approaches for stratification of therapy, generating insights into the mechanisms that underpin drug resistance, and deciphering pathways exploited by mesothelioma to enable metastasis. We have developed the first clinical platform to evaluate multiple novel targeted therapies for mesothelioma providing a frictionless research path from bench to bedside.
Dr Pranabashis Haldar
Clinical tuberculosis research. Many smaller clinical projects that would be suitable at Academic Foundation level can be offered, with results that will lead to abstracts at national and international conferences.
Professor Laura Gray
I am a statistician who specialises on the clinical area of diabetes. I am particularly interested in the identification of people with undiagnosed diabetes and those at risk, and in preventing diabetes. I would be interested in supporting a Foundation doctor in undertaking a systematic review and meta analysis in these areas (such as - is screening for undiagnosed diabetes in emergency departments worthwhile?).
Dr Nigel Langford
Clinical research project investigating the use of illicit drugs in patients presenting to the Emergency Department. The project will be based within the Emergency Department though trainees will be required to work within both the ITU and the Acute Medical unit. Trainees will have the opportunity to follow through samples to the pathology laboratory and undertake analysis if they wish.
Professor Gavin Murphy
As the Director of the University’s Clinical Trials Unit, I oversee a portfolio of clinical trials spanning multiple clinical areas (including cardiovascular, respiratory, diabetes, mental health, cancer, dermatology and public health) and all stages of development, from initial idea to final publication. Your placement would thus allow for both breadth and depth of exposure.
Professor Salman Siddiqui
Precision medicine, severe asthma precision medicine trials, imaging and early disease detection/risk stratification.
Dr Michael Steiner
Management of complex, advanced COPD.
Risk stratification in primary care in COPD.
Nutrition in chronic respiratory disease.
Professor Toru Suzuki
Clinical interest is in aortic cardiology with research interest in phenotyping patients with this disease using analytical techniques including epidemiology, laboratory (phenomics) and imaging approaches. There is another project in heart failure risk markers (biomarkers) using metabolic methods with a focus on the gut microbiome including therapeutic intervention.
Professor Anne Thomas
The Academic Foundation doctor would be integrated into the multi-disciplined team looking after patients with cancer receiving treatment on early phase clinical studies on the Hope Clinical Trials Facility. They would have the opportunity of being involved in the design, development and delivery of a study which would provide them great insight into a career in clinical research.
The research in our group focusses on improving diagnostic process and mechanisms of disease in paediatric ophthalmology. We use a range of techniques in phenotyping studies (using optical coherence tomography, eye movement recordings, electrodiagnostic tests) and molecular studies (next generation sequencing and analysis).